Adagio Medical Holdings, Inc. (ADGM)

Adagio Medical Holdings, Inc. (ADGM) Healthcare & Pipeline Overview

Adagio Medical Holdings, Inc. is a developmental-stage medical device company focused on developing and commercializing ablation technologies for cardiac arrhythmias. Their portfolio includes iCLAS, vCLAS, and Cryopulse catheters, targeting atrial fibrillation, atrial flutter, and ventricular tachycardia. The company operates within the competitive medical devices sector, focusing on innovative cryoablation and pulsed-field ablation solutions.

What Is the Investment Thesis for ADGM?

Adagio Medical Holdings, Inc. presents a focused investment opportunity within the electrophysiology market, specifically targeting cardiac arrhythmia ablation. The company's innovative cryoablation and pulsed-field ablation technologies, including the iCLAS, vCLAS, and Cryopulse catheters, address a significant unmet need in treating atrial fibrillation, atrial flutter, and ventricular tachycardia. Key value drivers include successful completion of clinical trials, regulatory approvals (FDA/EMA), and subsequent commercialization of their product portfolio. The company's small size ($9.74M market cap) offers potential for high growth, but also carries inherent risks associated with developmental stage companies. Upcoming clinical trial results and regulatory milestones represent key catalysts. The company's beta of 0.14 suggests low volatility compared to the broader market.

Based on FMP financials and quantitative analysis

ADGM Key Highlights

• Adagio Medical Holdings, Inc. is a developmental stage company focused on ablation technologies.
• The company's product portfolio includes iCLAS, vCLAS, and Cryopulse catheters.
• Adagio Medical targets atrial fibrillation, atrial flutter, and ventricular tachycardia.
• The company's market capitalization is $0.02B.
• Adagio Medical has a beta of 0.14, indicating lower volatility.

Who Are ADGM's Competitors?

ADGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ADGM's Key Strengths?

• Innovative ultra-low temperature cryoablation technology.
• Product portfolio addressing a range of cardiac arrhythmias.
• Experienced management team with expertise in medical devices.
• Strong intellectual property protection.
• Potential for significant growth in the expanding ablation market.

What Are ADGM's Weaknesses?

• Developmental stage company with limited commercial revenue.
• Reliance on successful clinical trials and regulatory approvals.
• Competition from larger, more established medical device companies.
• Limited financial resources compared to competitors.

What Could Drive ADGM Stock Higher?

• Completion of clinical trials for iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter.
• FDA and EMA regulatory submissions for iCLAS and vCLAS catheters.
• Announcement of strategic partnerships with hospitals or research institutions.
• Development and clinical evaluation of Cryopulse atrial pulsed-field cryoablation catheter.
• Expansion of intellectual property portfolio through new patent filings.

What Are the Key Risks for ADGM?

• Financial-distress signal — its Altman Z-Score of -5.05 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Delays or unfavorable outcomes in clinical trials.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from larger, more established medical device companies.
• Limited financial resources and dependence on future funding.
• Technological advancements by competitors that could render Adagio Medical's products obsolete.

What Are the Growth Opportunities for ADGM?

• Expansion into Pulsed-Field Ablation: Adagio Medical's Cryopulse catheter represents a significant growth opportunity in the rapidly evolving pulsed-field ablation market. Pulsed-field ablation is gaining traction due to its potential for more selective and safer ablation compared to traditional methods. The global pulsed-field ablation market is projected to experience substantial growth, offering Adagio Medical a chance to capture market share with its innovative technology. Timeline: Ongoing development and clinical trials with potential commercialization within the next 2-3 years.
• Regulatory Approvals and Commercialization: Securing regulatory approvals (FDA in the US, EMA in Europe) for its iCLAS, vCLAS, and Cryopulse catheters is a critical growth driver. Successful approvals will pave the way for commercialization and revenue generation. The regulatory pathway involves clinical trials, data submission, and agency review. Achieving these milestones will significantly enhance Adagio Medical's market value and competitive position. Timeline: Ongoing clinical trials and regulatory submissions with potential approvals within the next 1-2 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with hospitals, research institutions, and other medical device companies can accelerate Adagio Medical's growth. Collaborations can facilitate clinical trials, product development, and market access. Partnering with established players can provide access to distribution networks and expertise. Timeline: Ongoing efforts to establish partnerships with potential collaborations materializing within the next year.
• Expansion of Product Portfolio: Developing and launching new ablation technologies and products can broaden Adagio Medical's market reach and address a wider range of cardiac arrhythmias. This includes exploring new applications for its existing technologies and investing in research and development of novel ablation modalities. Timeline: Ongoing research and development efforts with potential new product launches within the next 3-5 years.
• Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia, represents a significant growth opportunity. These regions have a growing prevalence of cardiac arrhythmias and increasing adoption of advanced ablation technologies. Entering new markets requires regulatory approvals, distribution partnerships, and market-specific strategies. Timeline: Gradual expansion into select international markets over the next 3-5 years.

What Opportunities Does ADGM Have?

• Expansion into the rapidly growing pulsed-field ablation market.
• Strategic partnerships with hospitals and research institutions.
• Geographic expansion into Europe and Asia.
• Development of new ablation technologies and products.

What Threats Does ADGM Face?

• Regulatory hurdles and delays in obtaining approvals.
• Technological advancements by competitors.
• Changes in reimbursement policies for ablation procedures.
• Potential product liability claims.

What Are ADGM's Competitive Advantages?

• Proprietary ultra-low temperature cryoablation (ULTC) technology.
• Patented catheter designs and ablation techniques.
• First-mover advantage in specific ablation modalities.
• Strong relationships with key opinion leaders in electrophysiology.
• Growing intellectual property portfolio.

What Does ADGM Do?

Founded in 2011 and headquartered in Laguna Hills, California, Adagio Medical Holdings, Inc. is a developmental stage medical device company dedicated to transforming the treatment of cardiac arrhythmias through advanced ablation technologies. The company's inception was driven by the need for more effective and less invasive solutions for conditions like atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical's product portfolio includes the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories, designed for treating atrial fibrillation and atrial flutter. Additionally, they offer the vCLAS ventricular ULTC catheter, targeting ventricular tachycardia. The Cryopulse atrial pulsed-field cryoablation catheter and accessories represent their foray into pulsed-field ablation, a rapidly evolving area in cardiac arrhythmia treatment. As a developmental stage company, Adagio Medical is focused on clinical trials, regulatory approvals, and eventual commercialization of its innovative products. Their strategic focus is on providing comprehensive solutions for electrophysiologists to address a wide range of cardiac rhythm disorders.

What Products and Services Does ADGM Offer?

• Develop ablation technologies for cardiac arrhythmias.
• Offer treatments for atrial fibrillation.
• Offer treatments for atrial flutter.
• Offer treatments for ventricular tachycardia.
• Provide iCLAS atrial ultra-low temperature cryoablation (ULTC) catheters and accessories.
• Provide vCLAS ventricular ULTC catheters.
• Provide Cryopulse atrial pulsed-field cryoablation catheters and accessories.

How Does ADGM Make Money?

• Develop and patent novel ablation technologies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approvals (FDA, EMA) for commercialization.
• Manufacture and market ablation catheters and accessories.
• Generate revenue through sales of products to hospitals and electrophysiology centers.

What Industry Does ADGM Operate In?

Adagio Medical Holdings, Inc. operates within the medical device industry, specifically targeting the electrophysiology market. This market is characterized by increasing prevalence of cardiac arrhythmias, technological advancements in ablation techniques, and a growing demand for less invasive treatment options. The competitive landscape includes established players and emerging companies focused on cryoablation, radiofrequency ablation, and pulsed-field ablation. Adagio Medical aims to differentiate itself through its ultra-low temperature cryoablation technology and its expansion into pulsed-field ablation. The global cardiac ablation market is projected to reach billions of dollars in the coming years, driven by an aging population and increasing awareness of cardiac arrhythmias.

Who Are ADGM's Key Customers?

• Electrophysiologists
• Hospitals
• Cardiac arrhythmia treatment centers
• Patients with atrial fibrillation
• Patients with ventricular tachycardia

Net buyingInsider Activity

Over the past six months, Adagio Medical Holdings, Inc. insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 1.3M shares acquired (about $1.3M) — insiders putting money in tends to read as conviction.

ADGM Valuation & Market Position

With a $9.74M market cap, Adagio Medical Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ADGM's quantitative score of 29/100 is below the peer average of 78/100.

Key Financial Metrics

Return on assets is -62.0%, showing how much profit it generates from its asset base. A current ratio of 1.85 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -144.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Adagio Medical Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.05 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Adagio Medical Holdings, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.18.

Company Profile

Adagio Medical Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Laguna Hills, US. The company is led by CEO Todd Usen. ADGM has traded publicly since 2024.

ADGM Financials

ADGM Latest News

ADGM Analyst Consensus

ADGM MoonshotScore

Latest Adagio Medical Holdings, Inc. Analysis

Adagio Medical Holdings, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources